Last reviewed · How we verify
Enoxaparin 4000 IU
At a glance
| Generic name | Enoxaparin 4000 IU |
|---|---|
| Also known as | ENOXA®, LOVENOX® |
| Sponsor | Les Laboratoires des Médicaments Stériles |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth) (PHASE3)
- Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency (PHASE2)
- Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy (PHASE2)
- ANTIcoagulation in Severe COVID-19 Patients (PHASE2)
- Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
- Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia (PHASE2, PHASE3)
- Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® (PHASE4)
- Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparin 4000 IU CI brief — competitive landscape report
- Enoxaparin 4000 IU updates RSS · CI watch RSS
- Les Laboratoires des Médicaments Stériles portfolio CI